- Myriad Genetics' Precise MRD test demonstrates high survival rates in oligometastatic clear-cell renal cell carcinoma (ccRCC) patients.
- MRD-positive patients initiated systemic therapy within 27 months, while MRD-negative patients maintained on radiation therapy for 54 months.
- Precise MRD test detects MRD in more than 50% of baseline samples, showing advanced sensitivity in low tumor fractions.
Myriad Genetics (MYGN, Financial) has announced new clinical data for their Preciseâ„¢ MRD test in patients with oligometastatic clear-cell renal cell carcinoma (ccRCC) during the American Association for Cancer Research (AACR) Annual Meeting. The study highlighted that metastasis-directed radiation therapy allowed patients to delay or avoid systemic treatments while maintaining impressive survival rates of 94% at two years and 87% at three years.
Interestingly, the data showed that MRD-positive patients went on to start systemic therapy after a median of 27 months, whereas MRD-negative patients stayed on radiation therapy for a median of 54 months. The Precise MRD test was able to identify more than 50% of patients as MRD-positive at baseline, showcasing its superior detection abilities compared to first-generation tests, especially in ccRCC's challenging low tumor fractions.
Additional research findings included the optimization of tumor-informed MRD panels and the incorporation of INDEL mutations, which enhance the test's sensitivity in detecting circulating tumor DNA (ctDNA). Despite the promising results, it is important to note that the Precise MRD test is currently available only for research purposes in collaboration with academic and pharmaceutical investigators. This step is crucial in the development process, with potential for broader clinical implementation in the future.
